FDA Reviewers Disagreed About Approval Of Sprout's Addyi
Post-approval trials could lead to future regulatory action on the female sexual dysfunction drug, FDA staff say in NEJM editorial detailing the product's review.
Post-approval trials could lead to future regulatory action on the female sexual dysfunction drug, FDA staff say in NEJM editorial detailing the product's review.